- 1 A Health Economic Evaluation for Implementing an Extended Half-life Monoclonal
- Antibody for All Infants vs. Standard Care for Respiratory Virus Syncytial Prophylaxis in
 Canada
- 3 C 4
- 5 Thomas Shin MA, MPH^{1,2}, Jason KH Lee MSc Mbiotech, PhD (Candidate)^{1,3, α}, Alexia Kieffer
- 6 MSc, MPH, PhD⁴, Michael Greenberg MD, MPH⁴, Jianhong Wu PhD²
- 7
- ¹Sanofi, 1755 Steeles Ave W, North York, Ontario, Canada M2R 3T4
- 9 ²York University, Department of Mathematics and Statistics N520 Ross, 4700 Keele Street,
- 10 Toronto, Ontario, Canada M3J 1P3
- ³Leslie Dan School of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario,
- 12 Canada M5S 3M2
- 13 ⁴Sanofi, Lyon, France
- 14
- 15 **Corresponding author:** <u>thomas.shin@sanofi.com</u>
- 16 $^{\alpha}$ Jason KH Lee is a co-first author
- 17
- 18

19 Abstract

- 20 Respiratory syncytial virus (RSV) is a highly infectious virus, and infants and young children are
- 21 particularly vulnerable to its progression to severe lower respiratory tract illness (LRTI).
- 22 Nirsevimab, an extended half-life monoclonal antibody, was recently approved in Canada as a
- 23 passive immunization intervention for the prevention of RSV LRTI. A static decision tree model
- 24 was utilized to determine the cost-effectiveness of nirsevimab in Canadian infants compared to
- current standard of care (palivizumab for infants born preterm, and with specific chronic
- conditions) and generate an optimal price per dose (PPD) at accepted willingness-to-pay (WTP)
- thresholds. Various health outcomes (including hospitalization, ICU, and mechanical ventilation)
- and healthcare costs were calculated over one RSV season, with any necessary follow-up
- 29 prophylaxis in the second season for three infant categories (palivizumab-eligible, preterm, and
- term). All health-related parameters and costs were tailored to the Canadian environment.
- Compared to scenarios where only at-risk segments of the infant population received nirsevimab, the base area (administering nirsevimab to all infants in their first PSV access) use the user
- 32 the base case (administering nirsevimab to all infants in their first RSV season) was the most 33 a cost offective versus standard error the PPD was 6602 at a 640,000/0 ALV WTD the shall using
- cost-effective versus standard care: the PPD was \$692 at a \$40,000/QALY WTP threshold, using
 average costing data assumptions across all scenarios. Compared to standard care, the base case
- average costing data assumptions across an scenarios. Compared to standard care, the base case
 scenario could avoid 18,249 RSV-related health outcomes (reduction of 9.96%). Variations in
- discount rate, distribution of monthly RSV infections, nirsevimab coverage rate for infants born
- at term, and palivizumab cost had the most significant model impact. Passive immunization of all
- infants with nirsevimab can significantly reduce RSV-related health and economic burden across
- 39 Canada.
- 40 Keywords: respiratory syncytial virus (RSV), nirsevimab, infants, Canada, health economics,
- 41 passive immunizations

42 Introduction

Respiratory syncytial virus (RSV) is a highly infectious and prevalent viral pathogen with 43 activity that follows an annual seasonal pattern.^{1,2} Afflicting individuals of all ages, RSV is 44 45 transmitted via respiratory droplets and exhibits a typical presentation of mild upper respiratory tract symptoms such as sneezing, coughing and runny nose that resolve in 1-2 weeks.³ However, 46 47 subpopulations such as infants and young children are particularly vulnerable to more severe illness with RSV,⁴ presenting as acute lower respiratory tract infection (LRTI), most commonly 48 bronchiolitis and pneumonia. In Canada, RSV is the leading cause of hospitalization in children 49 four years and younger,⁵ and 80% of these children were born at term with no underlying health 50 51 conditions.⁶ While RSV-associated death rates are highest in infants who were born premature, the mortality burden is greatest in full-term infants given their proportionately large population.⁷ 52 For children who recover from RSV, early infection may also have long-lasting health 53 consequences, as indicated by associations with recurrent wheezing and pediatric asthma.⁸ 54 Infants are at the highest risk for severe manifestations of this virus during their first RSV 55 season,⁹ and nearly all children will be infected by two years of age;¹⁰ this high prevalence, 56 combined with the potential severity and long-term impact of RSV, signifies a tremendous unmet 57 58 medical need to protect infants from this infection.

RSV-related prophylaxis among infants represents a promising tool for reducing the significant health and economic burden of RSV in Canada. However, until recently, palivizumab, a monoclonal antibody, was the sole product available for RSV prevention in children and only indicated for infants meeting stringent criteria encompassing early gestational age and the presence of specific chronic conditions.¹¹ In order to protect all infants from severe RSV disease, an extended half-life humanized monoclonal antibody with neutralizing activity was developed.

Nirsevimab acts as a viral inhibitor by binding to the fusion protein on the surface of the RSV 65 virus.¹² Two clinical trials have demonstrated a statistically significant reduction in the incidence 66 of medically-attended (MA) RSV LRTI after nirsevimab administration compared to placebo in 67 preterm infants born during or entering their first RSV season, term and late preterm infants, and 68 in children up to 24 months of age who remain vulnerable to severe RSV disease through their 69 70 second RSV season due to being preterm or having chronic lung disease of prematurity or congenital heart disease.¹³⁻¹⁵ In Canada, nirsevimab is currently indicated for the prevention of 71 LRTI in neonates and infants during their first RSV season and in children up to 24 months at 72 high-risk for severe RSV disease in their second RSV season.¹⁶ In the US, the Advisory 73 Committee on Immunization Practices (ACIP) recently provided a unanimous recommendation 74 for the administration of nirsevimab to all infants aged <8 months born during or entering their 75 first RSV season and for those 8-19 months at increased risk for severe RSV entering their 76 second RSV season.¹⁷ Given the severity and seasonality of RSV, it is important to understand 77 78 the cost and clinical impact of different implementation scenarios within the pediatric population to ensure optimal and cost-effective protection. We implemented an externally validated 79 economic model comparing nirsevimab to the standard of care in Canada, utilizing various 80 81 willingness-to-pay (WTP) thresholds to determine the optimized price per dose for nirsevimab in Canada for the reduction of medically-attended RSV infections and hospitalizations from a 82 83 societal perspective.

84 Methods

85 Overview

A static decision tree model followed a cohort of Canadian newborn infants segmented into three
categories based on risks for severe RSV: 1) preterm infants (<37 weeks gestational age [WGA])

eligible to receive palivizumab ("palivizumab-eligible"); 2) healthy preterm infants (<37 weeks 88 wGA); and 3) infants born at term (\geq 37 wGA). The definition of palivizumab-eligible infants 89 was based on criteria reported in the Canadian literature.¹⁸ Based on Canadian RSV surveillance 90 data, the RSV season was assumed to increase in activity from November to the end of the 91 following March.¹⁶ In the base case scenario, all infants born outside and inside the RSV season 92 93 were administered nirsevimab during their first RSV season in the treatment arm (those born prior to the season received nirsevimab at the season's start), with a select proportion of preterm 94 95 infants receiving follow-up treatment in the subsequent season. Therefore, the newborn cohort was followed for two RSV seasons. The comparator arm was the standard of care (i.e., 96 palivizumab), which only applied to a small proportion of infants meeting Canada's strict 97 eligibility criteria.¹⁸ The model simulated the patient trajectory of RSV infection with health 98 99 outcomes, including RSV-related hospitalization, intensive care admission (ICU), mechanical ventilation (MV), emergency and general practitioner admissions (ER, GP), and RSV-related 100 101 mortality. Direct and indirect costs associated with MA RSV LRTI were integrated into the model, which assumed the societal perspective. All mortality-related costs and outcomes were 102 discounted at a rate of 1.5%, as recommended by national guidelines.¹⁹ 103

The model integrated the following elements: population data (segmented by palivizumabeligible, preterm, and term infants), seasonality of RSV, coverage and adherence rates, clinical profiles of therapies, RSV-related health outcomes (e.g., hospitalization, ICU, MV), outcomerelated utility values, and outcome specific costs. In order to capture the seasonality of RSV, the implementation scenarios of nirsevimab by subgroup (e.g., born in-season, born out-of-season, palivizumab-eligible, preterm, term), and an accurate assessment of price per dose, the economic model required granular (monthly) data inputs. These monthly inputs included population birth,

probability of RSV infection, and RSV-related health outcomes. A comprehensive list ofparameters utilized in the model is presented in Table 1.

113 Health Outcome Parameters

The grey and peer-reviewed literature was systematically reviewed to identify ongoing and 114 completed health economic, clinical, and epidemiological studies related to RSV and 115 palivizumab. Population-based data, with the subgroups of interest and the monthly probability 116 of infection, were derived from national statistics and surveillance data.^{20,21} All inputs for 117 118 nirsevimab were derived from Phase 2b and Phase 3 studies, while the grey literature provided insights into palivizumab's cost and clinical profile.^{13-15,18,22} Where possible, only up-to-date 119 Canadian inputs were utilized to populate the model; however, in the complete absence of such 120 121 data, US-specific inputs were adopted (e.g. data related to RSV-specific QALY loss and mortality outcomes). Data associated with RSV-related inpatient hospitalization, ICU 122 123 admissions, and patients requiring MV were generated per infant subgroup, using a combination 124 of average Canadian inputs and distributions of monthly US data (0-36 months age of infection). Informed by expert opinion, we assumed US-based monthly distributions as an acceptable proxy 125 for generating "Canadianized" values per subgroup. Figure 1 illustrates the distributional 126 conversion formula for generating Canadian values, utilizing an average of Canadian-specific 127 inputs (see Table 2). Furthermore, for ER and primary care admissions, US-based monthly 128 129 percentages (0-36 months age of infection) were utilized in the absence of monthly data for Canada.²³ 130

131 RSV-related input parameters are provided in Tables 1 and 2.

132

133 Economic Parameters

All costs are outlined in Table 3 with inflation adjustments using the Canadian Consumer Price 134 135 Index (CPI), and adjusted to 2023 Canadian dollars. Although the model adopts a national scope, 136 most RSV-specific costs within the past five years were from Ontario, Alberta, and Quebecspecific peer-reviewed sources due to availability.²⁴⁻²⁷ Furthermore, grey literature on the cost-137 138 effectiveness and recommended use of palivizumab provided overall support for model parametrization.^{18,22} Direct healthcare costs per RSV-related health outcome required the 139 140 establishment of a costing matrix with an average cost per health outcome by subgroup (i.e. palivizumab-eligible, preterm, and term infants). ER, GP, and direct non-medical costs per 141 142 hospitalization (i.e., travel, meals, childcare, and out-of-pocket expenses attributed to RSVrelated hospitalization) were assumed to be uniform across subgroups and remained constant 143 regardless of scenario analysis. In contrast, inpatient hospitalization, ICU, and MV costs required 144 calculations based on different sources. The primary costing scenario (S_0) was used for base case 145 146 modelling; intended as a representation of a broader Canadian costing perspective, it was generated by averaging all scenarios (S1a, S1b, S2, S3, and S4, as described below). For the 147 majority of the scenarios, the distribution of costs per subgroup were derived from McLaurin et 148 al.²⁸ For Scenario S1a and S1b, the recent Canadian literature from Rafferty et al. provided 149 150 average RSV-attributable lab-confirmed hospitalization costs within 30 days and 365 days postdiagnosis by age group.²⁷ Utilizing matrix algebra, the case-weighted cost for infants <1 year 151 was applied to the distribution from McLaurin et al. to establish values within the costing matrix 152 S1a and S1b.²⁸ In Scenario 2 (S2), cost outcomes were based on Thampi et al. (2021), with cost 153 differentials between palivizumab-eligible, preterm, and term infants but not across the different 154 health outcomes (e.g., inpatient hospitalization, ICU, MV).²⁶ Scenario 3 (S3), derived inputs 155

from Buchan et al. (2019), and applied a similar costing approach as S2.²⁷ Scenario 4 (S4)
utilized the detailed costs from Papenberg et al. (2020), where direct and indirect RSV-related
costs were sourced from multiple Quebec-specific resources (e.g. the Quebec government's
health insurance board Régie de l'assurance maladie du Québec [RAMQ], McGill University
Health Centre, etc.).²⁵

161 Costing Scenarios

The price per dose optimization scenarios were based on four WTP thresholds (incremental cost 162 163 per quality-adjusted life years [QALY]) of \$40,000, \$50,000, \$70,000, and \$100,000 per QALY, which represent the commonly accepted thresholds by North American health technology 164 assessment (HTA) bodies, such as Canada's Drug and Technology Agency (CADTH), Institut 165 166 national d'excellence en santé en services sociaux (INESSS), National Advisory Committee of Immunization (NACI), and Institute for Clinical and Economic Review (ICER).^{19,29-31} The 167 primary costing scenario (S_0) attempted to represent a pan-Canadian perspective by averaging 168 169 the costing matrices of all scenarios. Scenarios S1a and S1b utilized the average RSVattributable lab-confirmed hospitalization costs within 30 days and 365 days (for those <1 year of 170 age) to populate the costing matrix provided by McLaurin et al. Two additional scenarios (S2, 171 S3) derived inputs from Ontario-specific sources with no assumptions regarding underlying cost 172 distributions.^{26,27} In S2, costs were derived from Ontario's RSV-focused population-based match 173 cohort study.²⁶ Costs for inpatient hospitalization, ICU, and MV among the preterm infants 174 175 eligible for palivizumab were calculated based on the weighted mean adjusted costs for 176 congenital heart disease (CHD), hemodynamically significant CHD, congenital lung disease 177 (CLD), and birth between 22 and 28 wGA. Similar calculations were applied to preterm infants (29-35 wGA) and term infants (36-43 wGA or full-term with no comorbidities). Relative to the 178

| 179 | S ₀ , S1a, S1b, and S2, the Ontario-based costing data in S3 was less granular, providing two |
|-----|---|
| 180 | average costs for young children \leq 59 months with and without \geq 1 comorbidity. ²⁷ S4 was based |
| 181 | on Quebec-specific data providing the granular hospitalization costs attributed to RSV (e.g. |
| 182 | pediatric unit, perinatal ICU, neonatal ICU, short-stay unit, ER) across a wide scope of cost |
| 183 | outcomes ranging from hospital stay, administration, procedural, specialist, hospital discharge, |
| 184 | outpatient resource use, productivity, and out-of-pocket auxiliary costs. ²⁵ |
| 185 | Implementation Scenarios |
| 186 | For all costing scenarios (S ₀ , S1a, S1b, S2, S3, S4), analyses were conducted to explore the price |
| 187 | per dose contingent on the scope of program implementation. The scope included four |
| 188 | implementation scenarios: 1) all infants (i.e. palivizumab-eligible, preterm, and term) born |
| 189 | within and outside of the RSV season (base case scenario); 2) palivizumab-eligible and preterm |
| 190 | infants born within and outside of the RSV season (with the exclusion of term infants); 3) |
| 191 | palivizumab-eligible and preterm infants born within and outside of the RSV season, and term |
| 192 | infants 0-3 months entering their first RSV season and term infants born during the RSV season; |
| 193 | and 4) palivizumab-eligible and preterm infants born within and outside of the RSV season and |
| 194 | term infants born during the RSV season. |
| 195 | Deterministic Sensitivity Analyses |

A univariate sensitivity analysis was conducted to understand which variables significantly
impacted the price per dose. The lower and upper bounds from the 95% confidence intervals (CI)
were used where available; alternatively, we utilized a variance of ±20%.

199

201 **Results**

202 Price Per Dose

The price per dose of nirsevimab at the four WTP thresholds is presented in Table 4 for all 203 costing and implementation scenarios, including the base case, which was consistently the least 204 205 costly of the scenarios modelled. Using a WTP threshold of \$40,000 per QALY, immunizing all infants born in and out of season would be cost-effective from a societal perspective at a PPD of 206 692 for the primary costing scenario (S₀) and ranged from 634 to 769 depending on the 207 208 source of costing input; at the highest WTP threshold of 100,000/QALY, the PPD increased to 209 \$894 (range: \$836 to \$971). Of all costing scenarios, S3, which derived its costing input from an 210 Ontario-based RSV study that calculated costs for all children <59 months (stratified by presence 211 or absence of at least one comorbidity) rather than more granular age groups, consistently 212 yielded the lowest PPDs; the highest PPDs were generated by S1b, a scenario that used the average RSV-attributable lab-confirmed hospitalization costs within one year. 213 Of all implementation scenarios, immunizing only palivizumab-eligible children and those 214 215 preterm and born in and out of season generated the highest PPD for nirsevimab: \$3,767 at a 216 WTP threshold of \$40,000/QALY and \$4,126 at the highest threshold (i.e., \$100,000/QALY). **Clinical and Cost Impact** 217 218 A comparison was conducted of the clinical and cost impact of administering nirsevimab to all

219 infants (base case scenario) relative to the standard of care. Compared to current practice, the

base case implementation strategy could avoid 18,249 RSV-related health outcomes (9.96%),

including three inpatient deaths and 812 inpatient hospitalizations (Table 5). Use of the base case

strategy also could avoid 4,071 ER visits, a reduction of 10.2%. The reduction of health

outcomes is associated with a potential cost-savings of \$26,324,578 (range of \$19.7M to \$34.9M
for the additional scenarios utilizing short-term and long-term RSV-attributed hospitalization
costs, respectively), of which 63.6% could be attributed to a reduction in direct costs, primarily
derived from avoidance of hospitalization and ICU stays. The majority of both total outcomes
avoided (99.7%), and resultant cost-savings (97.5%) are attributed to providing nirsevimab as
RSV prophylaxis to otherwise healthy full-term and preterm children who are not eligible for
palivizumab.

230 Deterministic Sensitivity Analysis

The results of the univariate sensitivity analysis for the base case scenario (nirsevimab provided to all infants within and outside RSV season) at the \$40,000 WTP threshold are displayed in the Tornado diagram in Figure 4. The factors resulting in the most variation in PPD were the discount rate, the variance of distribution of monthly RSV, the coverage rate of nirsevimab for infants born at term, and the cost of palivizumab. [Figure 4 here]

236 Discussion

The approval of nirsevimab as RSV prophylaxis in Canada represents a valuable source of 237 protection for infants and young children against a disease that is associated with significant 238 morbidity and healthcare resource utilization. Our study demonstrates that compared to scenarios 239 where only specific segments of the infant population receive nirsevimab, administering 240 nirsevimab to all infants during their first RSV season was the most cost-effective scenario 241 compared to standard care, yielding a PPD of \$692 at a \$40,000/QALY willingness-to-pay 242 243 threshold. In comparison to current standard care, the base case could avoid 18,249 RSV-related health outcomes (reduction of 9.96%) for a cost savings of \$26,324,578. Our model estimates 244

that passive immunization of all infants with nirsevimab could prevent approximately 812
hospitalizations. The largest RSV-related hospitalization burden occurs in term and preterm
children who are otherwise healthy and, therefore, not eligible for palivizumab. While premature
infants are at the highest risk for severe RSV-related outcomes requiring hospitalization,^{32,33} they
comprise only a small percentage of the birth cohort (and therefore a smaller overall health and
cost burden) compared to healthy term and preterm infants.

251 Our sensitivity analysis revealed that increasing the discount rate, the variations in monthly 252 disease incidence and the cost of palivizumab, and decreasing nirsevimab coverage rate (our 253 model assumed a rate of 30%) would each result in a higher PPD for nirsevimab. Immunization programs are often sensitive to discounting since benefits may not be realized immediately, as 254 with conventional curative therapies.³⁴ Instead, there are often time delays between the time of 255 256 dose administration and when disease is averted, and discount rates become more impactful. We based our coverage rate assumption on influenza vaccine uptake in the infant population;³⁵ given 257 258 the potential risk and severity of influenza as a respiratory infection, particularly in infants, we deemed this an appropriate proxy. As nirsevimab becomes routinely administered in the United 259 States and elsewhere as part of RSV prophylaxis, a more informed coverage rate assumption will 260 261 be possible.

Unlike many other diseases, the seasonality of RSV translates to a substantial variation in risk of infection from month to month. Previous studies have demonstrated that RSV-associated hospitalizations and healthcare costs were the highest for children born between September and February, who, therefore, had early exposure to the virus, with rates peaking in December and declining into April and after.³⁶⁻³⁹ Due to this monthly change in viral risk combined with granularity in palivizumab and nirsevimab's current indications for use in Canada, we strived to

utilize monthly data inputs from Canada in our model. Given the lack of such data and the 268 common seasonality of RSV and similar incidence in infants in Canada and the United 269 States,^{40,41} we opted to extrapolate US-based health outcomes and cost inputs and modify them 270 using average Canadian values. Incorporating monthly data inputs was deemed critical to the 271 ability of our model to estimate the clinical and cost impact of nirsevimab vs. standard care. 272 273 Our costing scenarios were informed by recent Canadian studies, which used different models 274 and sources of data to evaluate the healthcare costs and burden of RSV in infants and young children²⁴⁻²⁷ Though the model by Rafferty estimates costs utilizing data from Alberta, it also 275 276 incorporates national RSV positivity data to estimate the incidence and may be more likely to have widespread applicability across Canada than if a province-specific rate was used. Rafferty's 277 278 study was also unique in that it calculated outcomes at 30 days and 365 days post-infection, a valuable stratification given the progression of RSV illness and the changing need for healthcare 279 resources. Thampi et al.'s model considered children under 24 months and examined direct 280 281 medical costs per hospitalized child with RSV over a 12-month period. While Buchan et al.'s model did the same for children under five years of age in an earlier publication, Thampi et al. 282 included attributable costs associated with ER visits, inpatient hospitalization, same-day 283 284 surgeries, inpatient rehabilitation, physician and outpatient diagnostic and laboratory services. The model by Papenburg et al. utilized Quebec data for RSV and LRTI hospitalizations among 285 286 infants younger than six months at the start of, or born during the RSV season, assessing costs up 287 to 30 days discharge. Given that these studies vary considerably in model inputs and age group granularity, and utilize data from different provinces, our base case analysis utilized an average 288 289 of these costing scenarios to capture a pan-Canadian perspective.

We calculated the optimal PPD of nirsevimab at various widely accepted WTP thresholds, as 290 Canada does not adhere to one official cost-effectiveness threshold to inform national and 291 provincial recommendations and decisions. At a \$40,000/QALY threshold, our model generated 292 a base case price per dose of \$692, with a range of \$634 to \$769, depending on the source of 293 costing input. Costing models from the United States Centers for Disease Control (CDC) and 294 295 Prevention's Advisory Committee on Immunization Practices (ACIP) have utilized a list price of \$445 USD (approximately \$600 CAD) per dose of nirsevimab.⁴² The Sanofi US health economic 296 model for nirsevimab vs. standard care assumed a price of \$500 USD (approximately \$670 297 CAD),⁴² which is the approximate private market list price in the US.⁴³ The current public CDC 298 vaccine price list (per dose) indicates a \$395 USD (\$530 CAD) public price and a \$495 USD 299 300 (\$665 CAD) private price regardless of the dose concentration. A recently published Canadian 301 cost-effectiveness study established nirsevimab's maximum price per dose (PPD) to range between \$575 and \$595 CAD based on a societal all-infant administration approach with 302 303 consideration for RSV-related mortality, differing efficacy profiles (i.e. sigmoidal versus constant), 80%-100% product uptake, and a \$50,000 per QALY willingness-to-pay (WTP) 304 threshold.⁴⁴ The analysis findings demonstrated that the larger the target infant population for 305 306 nirsevimab administration, the greater the reduction in RSV burden; the maximum PPD may 307 have been conservative given that there was no standard of care comparator for any subgroup of infants (i.e. palivizumab).⁴⁵ Therefore, our model's generated PPD for the base case scenario 308 309 seems well-aligned with current prices of nirsevimab from the literature, with additional PPDs, which are higher in maximum price based on alternative implementation scenarios targeting 310 select at-risk segments of the infant population. 311

Our analysis has several strengths, including the use of a range of hospitalization costing data 312 and a costing matrix to incorporate hospitalization-related costs per level of RSV risk, the 313 assessment of various immunization scenarios, the stratification of the infant population by 314 gestational age at birth, and the inclusion of various medically-attended health outcomes and 315 mortality. Furthermore, our model attempted to capture the variability of RSV-related burden 316 317 and costs based upon the most up-to-date Canadian-specific economic literature. However, our model has several limitations. As stated earlier, we assumed that Canadian RSV health-related 318 319 inputs would follow a US-based distribution; while this assumption was supported by the similar 320 incidence rates of RSV in both countries, differences in healthcare delivery, practice patterns and healthcare-seeking behaviour may have led to variation that we did not consider. We also 321 assumed that healthcare costs would differ between subgroups and adjusted our model's 322 hospitalization-related inputs according to the costing matrix; using US data to inform the matrix 323 324 may have introduced differences in our model. However, Canadian literature suggests that 325 hospitalization length of stay, need for ICU stay, and use of mechanical ventilation vary considerably based on wGA and underlying conditions, with the implication of significant 326 differences in cost between risk subgroups by province.²⁵ Based on our guidance from external 327 328 experts, we deemed that integrating this into our model would enhance its accuracy. Additionally, our model assumed that infants with RSV infection would be immune for the rest 329 330 of the study period and did not account for re-infection; the impact is likely low, given that previous studies report that re-infection is typically mild.¹⁰ Our model did not include the RSV-331 related costs associated with long-term sequelae such as asthma, wheezing, otitis media, and 332 reduced pulmonary function incurred after hospitalization, which has been linked to RSV.⁴⁶ 333

- 334 Our study demonstrates that a passive immunization strategy for all infants with nirsevimab
- could be cost-effective at a WTP threshold of \$40,000/QALY, provided the nirsevimab PPD is
- less than \$692. This implementation scenario could result in significant reductions in the health
- and economic burden of RSV in Canada compared to the current standard of practice of
- administering palivizumab to certain at-risk infants only.

339 Acknowledgements

- 340 Sanofi would like to acknowledge the input and feedback from various clinical and health
- 341 economic experts from multiple advisory boards across Canada for the refinement and
- 342 development of this costing model.

343 Declaration of Interest Statement

- 344 TS, JKHL, MG and AK are employees of Sanofi, the manufacturer of nirsevimab (jointly with
- AstraZeneca). JW currently serves as the Sanofi Industrial Research Chair.
- 346 Funding
- 347 This work was supported by Sanofi and AstraZeneca.

348 Author Contributions

- 349 Study conception, design, analysis, interpretation and manuscript development were lead and
- 350 supported by TS, JKHL, MG and AK; JW provided expertise in methodology and model
- validation. All authors reviewed and approved the final version of the manuscript and are
- accountable for all aspects of the work.

353 Data Availability

354 Please contact the primary author for any inquiries pertaining to the model and input data.

355

357 **References**

- 1. Li Y, Wang X, Broberg EK, Campbell H, Nair H, European RSV Surveillance Network.
- 359 Seasonality of respiratory syncytial virus and its association with meteorological factors in 13
- 360 European countries, week 40 2010 to week 39 2019. Euro Surveill. 2022;27(16):2100619. doi:
- 361 10.2807/1560-7917.ES.2022.27.16.2100619.
- 2. Radhakrishnan D, Ouedraogo A, Shariff SZ, McNally JD, Benchimol EI, Clemens KK. The
- association between climate, geography and respiratory syncytial virus hospitalizations among
- children in Ontario, Canada: a population-based study. BMC Infect Dis. 2020;20(1):157. doi:
- 365 10.1186/s12879-020-4882-6.
- 366 3. La Vla WV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle: clinical features,
- 367 pathophysiology, treatment, and prevention. J Pediatr. 1992;121(4):503-10. doi: 10.1016/s0022368 3476(05)81135-7.
- 369 4. Chatterjee A, Mavunda K, Krilov LR. Current State of Respiratory syncytial virus disease and
- 370 management. Infect Dis Ther. 2021;10(Suppl 1):5–16. doi: 10.1007/s40121-020-00387-2.
- 5. Schanzer DL, Saboui M, Lee L, Nwosu A, Bancej C. Burden of influenza, respiratory
- 372 syncytial virus, and other respiratory viruses and the completeness of respiratory viral
- identification among respiratory inpatients, Canada, 2003-2014. Influenza Other Respir Viruses.
- 374 2018;12(1):113-121. doi: 10.1111/irv.12497.
- 6. Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair M-A, Pojsupap S, Karnauchow
- 376 T, O'Hearn K, Yasseen AS, et al. Incidence of hospitalization for respiratory syncytial virus
- 377 infection amongst children in Ontario, Canada: a population-based study using validated health
- administrative data. PLoS ONE. 2016;11(3): e0150416. doi: 10.1371/journal.pone.0150416.

- 379 7. Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. Mortality
- associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the
- 381 United States: A birth cohort study from 1999 to 2018. J Infect Dis. 2022;226(Suppl 2):S246-
- 382 S254. doi: 10.1093/infdis/jiac127
- 383 8. Makrinioti H, Hasegawa K, Lakoumentas J, Xepapadaki P, Tsolia M, Castro-Rodriguez JA,
- 384 Feleszko W, Jartti T, Johnston SL, Bush A, Papaevangelou V, Camargo CA Jr, Papadopoulos
- 385 NG. The role of respiratory syncytial virus- and rhinovirus-induced bronchiolitis in recurrent
- 386 wheeze and asthma-A systematic review and meta-analysis. Pediatr Allergy Immunol.
- **387** 2022;33(3):e13741. doi: 10.1111/pai.13741.
- 388 9. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells
- E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute
- lower respiratory infections due to respiratory syncytial virus in young children in 2015: a
- **391** systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi: 10.1016/S0140-
- **392** 6736(17)30938-8.
- 10. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with
- respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-6. doi:
- **395** 10.1001/archpedi.1986.02140200053026.
- 11. Resch B. Product review on the monoclonal antibody palivizumab for prevention of
- respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138-2149. doi:
- **398** 10.1080/21645515.2017.1337614.
- 12. AstraZeneca Canada Inc, Sanofi Pasteur Ltd. Beyfortus (nirsevimab injection): solution for
- 400 injection, 100 mg/mL, intramuscular use, 50 mg single-use, pre-filled syringe, 100 mg single-

- 401 use, pre-filled syringe [product monograph]. Mississauga (ON): AstraZeneca Canada Inc.; 2022
 402 Nov 1.
- 403 13. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ,
- 404 Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term
- 405 infants. N Engl J Med. 2022;386(9):837-846. doi: 10.1056/NEJMoa2110275.
- 406 14. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Esser MT, Khan
- 407 AA, Dubovsky F, Villafana T, et al. Single-dose nirsevimab for prevention of RSV in preterm
- 408 infants. New Engl J Med. 2020;383(5):415-25. doi: 10.1056/NEJMoa1913556.
- 409 15. Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL,
- 410 Llapur CJ, Novoa JM, Llorens XS, et al. Nirsevimab for prevention of RSV in term and late-
- 411 preterm infants. N Engl J Med. 2023; 388(16):1533-1534. doi: 10.1056/NEJMc2214773.
- 412 16. Government of Canada. Respiratory syncytial virus: Canadian immunization guide.
- 413 [Accessed 2023 09 01] <u>https://www.canada.ca/en/public-health/services/publications/healthy-</u>
- 414 living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html
- 415 17. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez PJ, Kotton CN,
- 416 Mahon BE, Meyer S, Long SS, et al. Use of Nirsevimab for the Prevention of Respiratory
- 417 Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory
- 418 Committee on Immunization Practices United States, 2023. MMWR Morbidity and Mortality
- 419 weekly report. 2023;72:920-5.
- 420 18. National Advisory Committee on Immunization. An Advisory Committee Statement (ACS)
- 421 National Advisory Committee on Immunization (NACI) Recommended use of palivizumab to
- 422 reduce complications of respiratory syncytial virus infection in infants. In: Public Health Agency
- 423 of Canada (PHAC), editor. Ottawa, Canada, 2022.

- 424 19. Public Health Agency of Canada (PHAC). Guidelines for the economic evaluation of
- 425 vaccination programs in Canada. In: National Advisory Committee on Immunization, editor. 1
- 426 ed2023.
- 427 20. Statistics Canada. Table 13-10-0425-01 Live births by weeks of gestation 2022 [Accessed
- 428 2023 08 30] https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310042501
- 429 21. Public Health Agency of Canada (PHAC). Respiratory Virus Detections in Canada 2023
- 430 [Accessed 2023 08 30] https://www.canada.ca/en/public-health/services/surveillance/respiratory-
- 431 <u>virus-detections-canada.html</u>
- 432 22. National Advisory Committee on Immunization. Cost-effectiveness of palivizumab
- 433 prophylaxis for respiratory syncytial virus (RSV): a systematic review. In: (PHAC) PHAoC,
- editor. Ottawa 2023.
- 435 23. Lively JY, Curns AT, Weinberg GA, Edwards KM, Staat MA, Prill MM, Gerber SI, Langley
- 436 GE. Respiratory syncytial virus-associated outpatient visits among children younger than 24
- 437 months. J Pediatric Infect Dis Soc. 2019;8(3):284-6. doi: 10.1093/jpids/piz011.
- 438 24. Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M, Swenson LW,
- 439 MacDonald SE, Canadian Immunization Research Network (CIRN) investigators. Evaluating the
- 440 individual healthcare costs and burden of disease associated with RSV across age groups.
- 441 PharmacoEconomics. 2022;40(6):633-645. doi: 10.1007/s40273-022-01142-w.
- 442 25. Papenburg J, Saleem M, Teselink J, Li A, Caouette G, Massé É, Lanctot KL. Cost-analysis of
- 443 withdrawing immunoprophylaxis for respiratory syncytial virus in infants born at 33-35 weeks
- gestational age in Quebec: a multicenter retrospective study. Ped Infect Dis J. 2020;39(8):694-9.
- 445 doi: 10.1097/INF.00000000002719.

- 446 26. Thampi N, Knight BD, Thavorn K, Webster RJ, Lanctot K, Hawken S, McNally JD. Health
- 447 care costs of hospitalization of young children for respiratory syncytial virus infections: a
- 448 population-based matched cohort study. CMAJ Open. 2021;9(4):E948-e56. doi:
- 449 10.9778/cmajo.20200219.
- 450 27. Buchan SA, Chung H, Karnauchow T, McNally JD, Campitelli MA, Gubbay JB, Katz K,
- 451 McGeer AJ, Richardson DC, Simor A, et al. Characteristics and outcomes of young children
- 452 hospitalized with laboratory-confirmed influenza or respiratory syncytial virus in Ontario,
- 453 Canada, 2009-2014. Ped Infect Dis J. 2019;38(4):362-9. doi: 10.1097/INF.00000000002164.
- 454 28. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus
- 455 hospitalization outcomes and costs of full-term and preterm infants. Journal of Perinatology:
- 456 official journal of the California Perinatal Association. 2016;36(11):990-6. doi:
- 457 10.1038/jp.2016.113.
- 458 29. CADTH. Methods and Guidelines: Guidelines for the Economic Evaluation of Health
- 459 Technologies: Canada (4th Edition) 2017 [Accessed 2023 08 28]
- 460 https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_
- 461 <u>technologies_canada_4th_ed.pdf</u>.
- 462 30. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining
- the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries
- based on growth in life expectancy and health expenditures. The Lancet Global Health.
- 465 2023;11(6):e833-e42. doi: 10.1016/S2214-109X(23)00162-6.
- 466 31. Institute for Clinical and Economic Review (ICER). 2020-2023 Value Assessment
- 467 Framework. 2020.

| 468 | 32. Lanari M, | Anderson EJ, | Sheridan-Pereira M, | Carbonell-Estrany | y X, Paes B, | Rodgers-Gra | y |
|-----|---------------|--------------|---------------------|-------------------|--------------|-------------|---|
| | | | | | | | |

- 469 BS, Fullarton JR, Grubb E, Blanken M. Burden of respiratory syncytial virus hospitalisation
- 470 among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis
- 471 of seven studies. Epidemiol Infect. 2020148:e170. doi: 10.1017/S0950268820001661.
- 472 33. Figueras-Aloy J, Manzoni P, Paes B, Simoes EA, Bont L, Checchia PA, Fauroux B,
- 473 Carbonell-Estrany X. Defining the risk and associated morbidity and mortality of severe
- respiratory syncytial virus infection among preterm infants without chronic lung disease or
- 475 congenital heart disease. Infect Dis Ther. 2016;5(4):417-452. doi: 10.1007/s40121-016-0130-1.
- 476 34. World Health Organization: Immunization Vaccines and Biologicals. (2019). WHO guide for
- 477 standardization of economic evaluations of immunization programmes. [Accessed 2023 09
- 478 01] https://apps.who.int/iris/bitstream/handle/10665/329389/WHO-IVB-19.10-eng.pdf
- 479 35. Statistics Canada. Table 13-10-0096-25 Influenza immunization in the past 12 months, by480 age group.
- 481 36. Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A,
- 482 Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children
- 483 in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. doi: 10.1186/s12879-021484 06399-8.
- 485 37. Kramer R, Duclos A, Lina B, Casalegno J-S. Cost and burden of RSV-related hospitalisation
- 486 from 2012 to 2017 in the first year of life in Lyon. France Vaccine. 2018;36(45):6591–6593.
- 487 doi: 10.1016/j.vaccine.2018.09.029.
- 488 38. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo
- 489 O, Mejías A, Baraldi E, Papadopoulos NG, Nair H, Nunes MC, et al. Respiratory syncytial virus
- 490 seasonality: a global overview. J Infect Dis. 2018;217(9):1356–1364. doi: 10.1093/infdis/jiy056.

- 491 39. Hawkes MT, Lee BE, Kanji JN, Zelyas N, Wong K, Barton M, Mukhi S, Robinson JL.
- 492 Seasonality of respiratory viruses at Northern latitudes. JAMA Netw Open. 2021;4(9):e2124650.
- doi:10.1001/jamanetworkopen.2021.24650.
- 40. McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Simões EAF, Swerdlow DL.
- 495 Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic
- 496 review and meta-analysis. J Infect Dis. 2022;15;225(6):1100-1111. doi: 10.1093/infdis/jiaa752.
- 497 41. Buchan SA, Chung H, To T, Daneman N, Guttmann A, Kwong JC, Murti M, Aryal G,
- 498 Campigotto A, Chakraborty P, et al. Estimating the incidence of first RSV hospitalization in
- 499 children born in Ontario, Canada. J Pediatric Infect Dis Soc. 2023;12(7):421-430. doi:
- 500 10.1093/jpids/piad045.
- 42. National Center for Immunization and Respiratory Diseases. Economics of preventing
- respiratory syncytial virus lower respiratory tract infections (RSV LRTI) among US infants with
- nirsevimab a summary report comparing models from: Sanofi AND University of Michigan
- and CDC. [Accessed 2023 08 31]
- 505 https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-
- 506 pediatric-03-sanchez-508.pdf.
- 43. Centers for Disease Control and Prevention. CDC Vaccine Price List. [Accessed 2024 03 25]
- 508 https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-
- 509 list/index.html.
- 510 44. Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-
- 511 effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of
- 512 Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet
- 513 Regional Health Americas. 2023;28:100629.

- 45. Li X, Bilcke J, Beutels P. Pricey or priceless: cost-effectiveness of respiratory syncytial virus
- 515 (RSV) prevention in infants. Lancet Reg Health Am. 2023;29:100657. doi:
- 516 10.1016/j.lana.2023.100657.
- 46. Respiratory syncytial virus. In: Kimberlin DW, editor. Red Book: 2018 Report of the
- 518 Committee on Infectious Diseases. 31st ed. Elk Grove Village, IL: American Academy of
- 519 Pediatrics. 2018:682–692.
- 520 47. IQVIA. Synagis sales by SKU (50MG and 100MG) 2020.
- 48. Drysdale SB. A Phase 3 randomized open-label study of nirsevimab (versus no intervention)
- 522 in preventing hospitalizations due to respiratory syncytial virus (RSV) in infants (HARMONIE)
- 523 [Oral presentation]. ESPID 2023; Lisbon, Portugal 2023.
- 49. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal
- antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane
- 526 Database Syst Rev. 2013;(4): CD006602. doi: 10.1002/14651858.CD006602.pub4.
- 527 50. Food and Drug Administration (FDA). Highlights of prescribing information: BEYFORTUS
- 528 (Product Monograph) 2023 [Accessed 2023 08 29]
- 529 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf.
- 530 51. Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL. Adherence to palivizumab for
- respiratory syncytial virus prevention in the Canadian registry of palivizumab. Pediatr Infect Dis
- 532 J. 2015;34(12):e290-7. doi: 10.1097/INF.000000000000922.
- 533 52. Butt ML, Elliott L, Paes BA. Respiratory syncytial virus hospitalization and incurred
- morbidities the season after prophylaxis. Paediatr Child Health. 2018;23(7):441-6. doi:
- 535 10.1093/pch/pxy046.
- 53. Statistics Canada. Table 13-10-0713-01 Infant deaths and mortality rates, by age group.

- 537 54. Statistics Canada. Table 13-10-0710-01 Mortality rates, by age group.
- 538 55. Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and
- respiratory syncytial virus in the US, 1999-2018. JAMA Network Open. 2022;5(2):e220527. doi:
- 540 10.1001/jama.289.2.179.
- 541 56. Hutton DW. Economic analysis of nirsevimab in pediatric populations. University of
- 542 Michigan; 2023 [Accessed 2023 08 29]
- 543 https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-
- 544 Pediatric-02-Hutton-508.pdf
- 545 57. Guertin JR, Feeny D, Tarride J-E. Age- and sex-specific Canadian utility norms, based on the
- 546 2013-2014 Canadian Community Health Survey. CMAJ. 2018;190(6):E155-E61. DOI:
- 547 https://doi.org/10.1503/cmaj.170317.
- 548 58. Statistics Canada. Canadian Vital Statistics, Death Database and Demography Division
- 549 (population estimates) [Accessed 2023 08 23]
- 550 https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3233
- 551 59. Hodgson D, Atkins KE, Baguelin M, Panovska-Griffiths J, Thorrington D, van Hoek AJ,
- 552 Zhao H, Fragaszy E, Hayward AC, Pebody R. Estimates for quality of life loss due to respiratory
- syncytial virus. Influenza and other respiratory viruses. Influenza Other Respir Viruses.
- 554 2020;14(1):19-27. doi: 10.1111/irv.12686.
- 555 60. Feltes TF, Simoes E. Palivizumab prophylaxis in haemodynamically significant congenital
- beart disease. Arch Dis Childhood. 2005;90(8):875-7; doi. 10.1067/s0022-3476(03)00454-2
- 557 61. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA,
- 558 Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated

- hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341-8. doi:
- **560** 10.1542/peds.2013-0303.
- 561 62. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus
- 562 monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-
- risk infants. Pediatrics.1998;102(3 Pt 1):531-7.
- 63. Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E,
- 565 Como-Sabetti K, Reingold A, et al. Estimated burden of community-onset respiratory syncytial
- virus-associated hospitalizations among children aged <2 years in the United States, 2014-15. J
- 567 Pediatric Infect Dis Soc. 2020;9(5):587-95. doi: 10.1093/jpids/piz087.
- 568 64. Mitchell I, Defoy I, Grubb E. Burden of respiratory syncytial virus hospitalizations in
- 569 Canada. Can Respir J. 2017:4521302. doi: 10.1155/2017/4521302.
- 570

571 Table 1. Key model inputs

| Parameter | Input | Range | Source |
|---|---------------------|-------|---|
| Population | | | |
| Total annual births in Canada | 367,684 | - | Statistics Canada ⁽²⁰⁾ |
| Estimated number of PVZ-eligible infants | 6,711 (1.83%) | - | Calculations based on Statistics Canada ⁽²⁰⁾ and IQVIA ⁽⁴⁷⁾ |
| Estimated number of preterm infants (<37 wGA) | 22,497 (6.12%) | - | Calculation based on Statistics Canada ⁽²⁰⁾ |
| Estimated number of term infants (≥37 wGA) | 338,476 (92.06%) | - | Calculation based on Statistics Canada ⁽²⁰⁾ |
| Percent of PVZ-eligible infants in 2 nd season | 10% | - | Expert opinion |
| Seasonality of Disease | | | |
| April | 7.81% | - | |
| May | 3.32% | - | |
| June | 1.70% | - | |
| July | 0.58% | - | |
| August | 0.75% | - | |
| September | 2.33% | - | Public Health Agency of |
| October | 5.20% | - | Canada ⁽²¹⁾ |
| November | 6.76% | - | |
| December | 17.37% | - | |
| January | 21.40% | - | |
| February | 18.23% | - | |
| March | 14.56% | - | |
| Clinical Profile | | | |

| | 1 | | | |
|--|------------|-----------------|---|--|
| | | | Griffin et al. $(2020)^{(14)}$, | |
| Nirsevimab duration of protection | 5 months | - | Hammitt et al. $(2022)^{(13)}$, | |
| | | | Muller et al. $(2023)^{(15)}$ | |
| Efficiency of ninearizath energy DVZ eligible | | | Drysdale et al. (2023) ⁽⁴⁸⁾ | |
| Efficacy of nirsevimab among PVZ-eligible preterm infants ¹ | 51% | - | Andabaka et al. (2013) ⁽⁴⁹⁾ | |
| Efficacy of nirsevimab among preterm infants | 86.2% | - | FDA (2023) ⁽⁵⁰⁾ | |
| Efficacy of nirsevimab among term infants | 76.8% | - | Muller et al. (2023) ⁽¹⁵⁾ | |
| Efficacy of PVZ | 51% | - | Andabaka et al. (2013) ⁽⁴⁹⁾ | |
| | | - | Chan et al. $(2015)^{(51)}$, | |
| First and second season coverage rate of PVZ | | | Butt et al. (2018) ⁽⁵²⁾ | |
| among PVZ-eligible preterm infants | 81%, 10% | | modified with expert | |
| among r vz-engible preterm infants | | | opinion (second season | |
| | | | coverage) | |
| First and second season coverage rate of | 81%, 10% | - | Assumption based on | |
| nirsevimab among PVZ-eligible preterm infants | 0170, 1070 | | palivizumab | |
| First season coverage rate for nirsevimab among | 30% | - | Statistics Canada ⁽³⁵⁾ | |
| preterm and term infants ² | | | Statistics Callada | |
| All-cause mortality among infants by age (per | , | | | |
| 0-5 months | 0.004 | | Statistics Canada ⁽⁵³⁾ | |
| 6-11 months | 0.0003 | | Statistics Canada ⁽⁵³⁾ | |
| 12-59 months | 0.0002 | | Statistics Canada ⁽⁵⁴⁾ | |
| Overall risk of RSV-related mortality | | | | |
| Preterm infants (including those PVZ-eligible) | 0.03% | | NACI ⁽¹⁸⁾ | |
| Term infants | 0.0024% | | Hansen et al. (2022) ⁽⁵⁵⁾ | |
| Lifetime QALY loss per RSV event | | | | |
| Inpatient hospitalizations | 0.017 | 0.0101 - 0.0726 | | |
| ICU admission | 0.017 | 0.0101 - 0.0726 | | |
| Mechanical ventilation (MV) | 0.017 | 0.0101 - 0.0726 | Hutton et al. (2023) ⁽⁵⁶⁾ | |
| Emergency room (ER) visit | 0.0134 | 0.0079 - 0.0455 | | |
| Primary care (GP) visit | 0.0085 | 0.0049 - 0.0455 | | |
| Parent/caregiver QALY loss | 0.005 | | | |
| Lifetime QALY loss with Premature Death | | | | |
| | | | Calculation based on | |
| PVZ-eligible, preterm, and term infants | 41 607 | | Guertin et al. (2018) ⁽⁵⁷⁾ , | |
| r v Z-engible, preterin, and term infants | 41.697 | - | Statistics Canada ⁽⁵⁸⁾ , and | |
| | | | Hodgson et al. (2020) ⁽⁵⁹⁾ | |
| Discount rate | 1.5% | - | CADTH ⁽²⁹⁾ | |
| • | | | | |

¹PVZ refers to palivizumab; In the absence of published evidence, we assumed nirsevimab was equal in efficacy to
 palivizumab

²Conservative assumption that first season coverage of nirsevimab among healthy preterm and term infants would

575 mirror influenza vaccine coverage among infant group

576

577 **Caption:** Table 1 is a comprehensive list of all key model inputs, including population

assumptions, risks associated with seasonality of RSV, clinical profiles of nirsevimab and

579 palivizumab, mortality rates and lifetime QALY losses related to RSV.

580 Table 2. Health-related inputs

| Age at time of infection (months) | PVZ-eligible infants | Preterm infants | Term Infants | Source |
|---|----------------------|-----------------|--------------|---------------------------------------|
| 0 | 13.18% | 3.32% | 1.89% | |
| 1 | 25.28% | 6.37% | 3.63% | |
| 2 | 13.96% | 3.52% | 2.00% | Feltes et al. |
| 3 | 10.05% | 2.53% | 1.44% | $(2015)^{(60)}$ |
| 4 | 8.69% | 2.19% | 1.25% | Hall et al. |
| 5 | 4.68% | 1.18% | 0.67% | $(2013)^{(61)}$ |
| 6 | 4.00% | 1.01% | 0.57% | IMPACT RSV |
| 7 | 5.47% | 1.38% | 0.78% | Study Group (2018) ⁽⁶²⁾ |
| 8 | 3.32% | 0.84% | 0.48% | McLaurin et al. |
| 9 | 3.71% | 0.93% | 0.53% | $(2016)^{(28)}$ |
| 10 | 3.61% | 0.91% | 0.52% | Schanzer et al. |
| 11 | 2.83% | 0.71% | 0.41% | $(2018)^{(5)}$ |
| 12-24 | 2.50% | 0.59% | 0.20% | (2010) |
| 25-36 | 2.50% | 0.59% | 0.20% | |
| Intensive Care U | nit (ICU) | | | |
| 0 | 43.36% | 60.35% | 18.81% | |
| 1 | 43.36% | 60.35% | 18.81% | |
| 2 | 43.36% | 60.35% | 18.81% | |
| 3 | 19.66% | 15.43% | 13.95% | |
| 4 | 19.66% | 15.43% | 13.95% | |
| 5 | 19.66% | 15.43% | 13.95% | Arriola et al. |
| 6 | 11.42% | 9.28% | 10.31% | $(2020)^{(63)}$ |
| 7 | 11.42% | 9.28% | 10.31% | Mitchell et al. |
| 8 | 11.42% | 9.28% | 10.31% | $(2017)^{(64)}$ |
| 9 | 11.42% | 9.28% | 10.31% | |
| 10 | 11.42% | 9.28% | 10.31% | |
| 11 | 11.42% | 9.28% | 10.31% | |
| 12-24 | 18.67% | 31.26% | 10.92% | |
| 25-36 | 18.67% | 31.26% | 10.92% | |
| Mechanical Venti | ilation (MV) | | | |
| 0 | 14.62% | 22.20% | 8.20% | |
| 1 | 14.62% | 22.20% | 8.20% | |
| 2 | 14.62% | 22.20% | 8.20% | |
| 3 | 5.69% | 6.80% | 1.82% | |
| 4 | 5.69% | 6.80% | 1.82% | Arriola et al. |
| 5 | 5.69% | 6.80% | 1.82% | $(2020)^{(63)}$ |
| 6 | 5.69% | 4.72% | 1.82% | Buchan et al. |
| 7 | 5.69% | 4.72% | 1.82% | $(2019)^{(27)}$ |
| 8 | 5.69% | 4.72% | 1.82% | (2017) |
| 9 | 5.69% | 4.72% | 1.82% | |
| 10 | 5.69% | 4.72% | 1.82% | |
| 11 | 5.69% | 4.72% | 1.82% | |
| 12-24 | 1.37% | 1.13% | 2.73% | |

| 25-30 | 1.37% | 1.13% | 2.73% | |
|--------------------------|--------|--------|--------|-----------------|
| Emergency Room (E | (R) | | | |
| 0 | 1.96% | 1.96% | 1.96% | |
| 1 | 6.42% | 6.42% | 6.42% | |
| 2 | 7.24% | 7.24% | 7.24% | |
| 3 | 10.52% | 10.52% | 10.52% | |
| 4 | 11.60% | 11.60% | 11.60% | |
| 5 | 7.13% | 7.13% | 7.13% | |
| 6 | 8.18% | 8.18% | 8.18% | Lively et al. |
| 7 | 5.61% | 5.61% | 5.61% | $(2019)^{(23)}$ |
| 8 | 5.56% | 5.56% | 5.56% |] |
| 9 | 5.56% | 5.56% | 5.56% | |
| 10 | 4.04% | 4.04% | 4.04% | |
| 11 | 5.56% | 5.56% | 5.56% | |
| 12-24 | 5.30% | 5.30% | 5.30% | |
| 25-36 | 5.30% | 5.30% | 5.30% | |
| Primary Care (GP) | | | | |
| 0 | 8.52% | 8.52% | 8.52% | |
| 1 | 18.79% | 18.79% | 18.79% | |
| 2 | 23.42% | 23.42% | 23.42% | |
| 3 | 23.26% | 23.26% | 23.26% | 1 |
| 4 | 26.50% | 26.50% | 26.50% | 1 |
| 5 | 28.92% | 28.92% | 28.92% | |
| 6 | 26.47% | 26.47% | 26.47% | Lively et al. |
| 7 | 20.72% | 20.72% | 20.72% | $(2019)^{(23)}$ |
| 8 | 27.78% | 27.78% | 27.78% | 1 |
| 9 | 22.72% | 22.72% | 22.72% | 1 |
| 10 | 24.17% | 24.17% | 24.17% | 1 |
| 11 | 25.81% | 25.81% | 25.81% |] |
| 12-24 | 18.03% | 18.03% | 18.03% |] |
| 25-36 | 18.03% | 18.03% | 18.03% | |

581 Abbreviation PVZ: palivizumab

Caption: Health-related inputs for RSV are presented in Table 2 by wGA and infant category

583 risk for this disease.

584

585

586

587

588

590 Table 3. Cost-related inputs

| Direct Costs ¹ | | | | | | |
|--|------------------|--|---------------------------------------|--------------------------------|--|--|
| Health Outcomes | Scenarios | Averation Averatioa Averatioa Averatioa Averatioa Averatioa Averatioa Averat | verage cost per Preterm infants | event (CAD) Term infants | Source ¹ | |
| ER visits | All scenarios | | \$836 | | Weighted average costs based on Thampi et al. (2021) ⁽²⁶⁾ and Papenburg et al. (2020) ⁽²⁵⁾ | |
| Primary care (GP) visits | All scenarios | | \$94 | | Papenburg et al. $(2020)^{(25)}$ | |
| Direct non- medical costs per inpatient hospitalization | All scenarios | \$652 | \$652 | \$220 | Papenburg et al. (2020) ⁽²⁵⁾ | |
| Inpatient hospitalization | | \$24,310 | \$11,380 | \$8,134 | Rafferty et al. $(2022)^{(24)}$ | |
| ICU admission | | \$48,301 | \$27,661 | \$21,238 | Thampi et al. (2021) ⁽²⁶⁾ | |
| Mechanical ventilation | S_0^2 | \$130,943 | \$98,165 | \$40,601 | Buchan et al. $(2019)^{(27)}$ Papenberg et al. $(2020)^{(25)}$ | |
| Inpatient hospitalization | | \$25,918 | \$8,374 | \$5,968 | | |
| ICU admission | S1a ² | \$54,693 | \$24,381 | \$23,326 | 1 | |
| Mechanical ventilation | | \$89,667 | \$39,251 | \$49,039 | Rafferty et al. | |
| Inpatient hospitalization | | \$52,333 | \$16,908 | \$12,050 | $(2022)^{(24)}$ | |
| ICU admission | S1b ² | \$110,434 | \$49,229 | \$47,100 | _ | |
| Mechanical ventilation | | \$181,052 | \$79,254 | \$99,018 | | |
| Inpatient hospitalization | | \$25,529 | \$13,848 | \$9,462 | The second set of | |
| ICU admission | S2 | \$25,529 | \$13,848 | \$9,462 | Thampi et al. $(2021)^{(26)}$ | |
| Mechanical ventilation | | \$25,529 | \$13,848 | \$9,462 | $(2021)^{(26)}$ | |
| Inpatient hospitalization | | \$9,268 | \$9,268 | \$6,104 | | |
| ICU admission | S 3 | \$9,268 | \$9,268 | \$6,104 | Buchan et al. $(2019)^{(27)}$ | |
| Mechanical ventilation | | \$9,268 | \$9,268 | \$6,104 | (2019)(27) | |
| Inpatient hospitalization | S4 | \$8,503 | \$8,503 | \$7,086 | Papenberg et $(2020)^{(25)}$ | |
| ICU admission | | \$41,581 | \$41,581 | \$20,196 | al. $(2020)^{(25)}$ | |

| Mechanical ventilation | | \$349,202 | \$349,202 | \$39,384 | |
|--|---------------|---------------------|-----------|---|---|
| Cost of Prophylaxi | S | | | | |
| PVZ | All scenarios | | \$1,599 | | |
| Indirect Costs | | | | | |
| Average hourly earnings of all employees | All scenarios | | \$25.39 | | Papenburg et al. (2020) ⁽²⁵⁾ |
| Number of hours per workday | All scenarios | | 8 hours | | |
| Lost days per RSV episode (Inpatient) | All scenarios | 5.35 days 2.56 days | | Mitchell et al. $(2017)^{(64)}$ | |
| Lost days per RSV episode (Outpatient) | All scenarios | 1.30 days 1.40 days | | Papenburg et al. (2020) ⁽²⁵⁾ | |

591 Abbreviation PVZ: palivizumab

¹All costs from each source were adjusted for inflation to 2023 based on the latest consumer price index
 (CPI)

²S1, S1a, S1b costing matrix was modelled based on the cost distribution from McLaurin et al. $(2016)^{28}$

595 For S1, the case-weighted midpoint (average) direct hospital costs (<365 days but >30 days) for infants

596 <1 year of age was \$21,342 based on Rafferty et al. (2022). For S1a, the average case-weighted within 30

day RSV-attributable cost was \$14,138 (6% CPI adjusted) for infants <1 year of age. For S1b, the average

case-weighted within 365 day RSV-attributable cost was \$28,546 (6% CPI adjusted) for infants <1 year

of age. For each scenario, the midpoint/average case-weighted costs were used to generate the costing

600 matrix according to McLaurin et al. $(2016)^{28}$ 601

602

603 Caption: Table 3 displays the RSV-related healthcare resource costs utilized in the model,

stratified by infant risk for RSV.

Table 4. Scenario-based price per dose (\$CAD) of nirsevimab at various willingness-to-pay (WTP) thresholds

| | | | Implementation | n Scenarios | |
|-----------------------------------|--|--|---|--|---|
| Costing Scenarios ¹ | Willingness- to-pay threshold (\$ CAD/QALY) | All-infants born in & out-season (BASE CASE) | PVZ-eligible & preterm born in & out- season | PVZ-eligible & preterm born in & out-season, term infants (0-3 months) in 1st season and term infants born in- season | PVZ-eligible & preterm born in & out-season, term infants born in- season |
| S ₀ | | \$ 692 | \$ 3,767 | \$ 874 | \$ 1,117 |
| S1a | | \$ 677 | \$ 3,678 | \$ 854 | \$ 1,092 |
| S1b | 40.000 | \$ 769 | \$ 3,875 | \$ 974 | \$ 1,235 |
| S2 | 40,000 | \$ 660 | \$ 3,618 | \$ 829 | \$ 1,052 |
| S3 | | \$ 634 | \$ 3,565 | \$ 795 | \$ 1,018 |
| S4 | | \$ 721 | \$ 4,100 | \$ 918 | \$ 1,187 |
| S ₀ | | \$ 726 | \$ 3,827 | \$ 908 | \$ 1,149 |
| S1a | 50,000 | \$ 711 | \$ 3,738 | \$ 888 | \$ 1,124 |
| S1b | | \$ 803 | \$ 3,935 | \$ 1,008 | \$ 1,267 |
| S2 | | \$ 694 | \$ 3,678 | \$ 863 | \$ 1,088 |
| S3 | | \$ 667 | \$ 3,625 | \$ 829 | \$ 1,049 |
| S4 | | \$ 755 | \$ 4,160 | \$ 952 | \$ 1,218 |
| S ₀ | | \$ 793 | \$ 3,946 | \$ 976 | \$ 1,213 |
| S1a | | \$ 778 | \$ 3,857 | \$ 956 | \$ 1,187 |
| S1b | 70.000 | \$ 870 | \$ 4,054 | \$ 1,075 | \$ 1,330 |
| S2 | 70,000 | \$ 762 | \$ 3,797 | \$ 930 | \$ 1,152 |
| S3 | | \$ 735 | \$ 3,745 | \$ 897 | \$ 1,113 |
| S4 | | \$ 823 | \$ 4,279 | \$ 1,020 | \$ 1,282 |
| S ₀ | | \$ 894 | \$ 4,126 | \$ 1077 | \$ 1,308 |
| S1a | 100,000 | \$ 879 | \$ 4,036 | \$ 1057 | \$ 1,283 |
| S1b | | \$ 971 | \$ 4,233 | \$ 1,177 | \$ 1,426 |
| S2 | | \$ 863 | \$ 3,976 | \$ 1,032 | \$ 1,247 |
| S3 | | \$ 836 | \$ 3,924 | \$ 998 | \$ 1,209 |
| S4 | | \$ 924 | \$ 4,459 | \$ 1,121 | \$ 1,378 |

607 Abbreviation PVZ: palivizumab

¹S₀: costing scenario used in base case with average costs derived from S1a, S1b, S2, S3, and S4; S1a: costs derived from Rafferty et al. (2023) representing costs within 30 days post-RSV infection; S1b: costs derived from Rafferty

et al. (2023) representing costs within 365 days post-RSV infection; S2: scenario based on costs derived from

Thampi et al. (2020); S3: scenario based on costs derived from Buchan et al. (2019); S4: scenario based on costs

612 derived from Papenberg et al. (2020)

| 613 | Caption: Price per dose | e (PPD) at the four studied WTP thres | holds are presented in Table 4, per |
|-----|-------------------------|---------------------------------------|-------------------------------------|
|-----|-------------------------|---------------------------------------|-------------------------------------|

614 costing scenario and implementation scenario.

| | Current | Current available standard of care ¹ | | | Nirsevimab ² | | T (1 |
|--|--------------------------------|---|---------------|-------------------------|-------------------------|---------------|----------------------------------|
| | PVZ-eligible infants | Preterm infants | Term infants | PVZ-eligible infants | Preterm infants | Term infants | Total Difference ³ |
| Health outcomes | | | | | | | |
| Inpatient hospitalizations (including ICU and MV) | 514 | 564 | 4,460 | 501 | 472 | 3,753 | -812 |
| ICU | 178 | 271 | 887 | 172 | 221 | 736 | -207 |
| MV | 40 | 66 | 216 | 39 | 53 | 179 | -51 |
| ER visits | 607 | 2,460 | 37,018 | 598 | 2,178 | 33,238 | -4,071 |
| GP visits | 2,118 | 8,518 | 128,164 | 2,095 | 7,592 | 115,750 | -13,363 |
| Inpatient deaths | 1 | 7 | 8 | 1 | 5 | 7 | -3 |
| Total health outcomes | 3,240 | 11,549 | 169,650 | 3,195 | 10,247 | 152,748 | -18,249 |
| Cost outcomes based | l on S ₀ (average o | of all scenarios) ³ | | | | | |
| Inpatient | | | | | | | |
| hospitalizations | \$8,133,343 | \$3,318,949 | \$28,984,272 | \$7,957,524 | \$2,835,394 | \$24,457,073 | -\$5,186,573 |
| ICU | \$6,615,125 | \$5,654,181 | \$14,203,343 | \$6,402,562 | \$4,650,320 | \$11,802,385 | -\$3,617,382 |
| MV | \$5,277,781 | \$6,515,735 | \$8,777,694 | \$5,090,006 | \$5,156,856 | \$7,240,593 | -\$3,083,755 |
| ER visits | \$503,259 | \$2,041,588 | \$30,548,015 | \$495,614 | \$1,805,919 | \$27,406,257 | -\$3,385,072 |
| GP visits | \$197,626 | \$795,965 | \$11,975,770 | \$195,458 | \$708,801 | \$10,807,350 | -\$1,257,752 |
| Direct non-medical costs per inpatient hospitalization | \$333,530 | \$366,501 | \$980,258 | \$325,015 | \$306,143 | \$824,352 | -\$224,779 |
| Total direct costs | \$21,060,664 | \$18,692,920 | \$95,469,351 | \$20,466,179 | \$15,463,432 | \$82,538,009 | -\$16,755,315 |
| Total indirect costs (excluding mortality) | \$1,269,837 | \$3,489,878 | \$48,957,742 | \$1,247,136 | \$3,070,157 | \$43,983,581 | -\$5,416,583 |
| Cost of inpatient death | \$7,431,138 | \$27,984,473 | \$33,683,455 | \$7,382,997 | \$26,003,892 | \$31,559,497 | -\$4,152,680 |
| Total Cost | \$29,761,639 | \$50,167,271 | \$178,110,548 | \$29,096,312 | \$44,537,481 | \$158,081,087 | -\$26,324,578 |

Table 5. Comparative clinical and cost outcomes between existing therapy and nirsevimab for all newborn infants (born within and outside the RSV season)

617 Abbreviation PVZ: palivizumab

| 618 619 | ¹ Current available standard of care is palivizumab, which is only offered, under strict criteria, to high-risk preterm infants who meet the age, comorbidity, seasonal, and/or geographic community for prophylaxis |
|------------|---|
| 620 621 | ² In the base case scenario, nirsevimab is offered to all infants entering the RSV season born within or outside the RSV season |
| 622 | ³ The base case scenario represents a wide spectrum of short-term and long-term costs across Canada (i.e. Alberta, |
| 623 | Ontario, Quebec) specific to RSV-related hospitalization among infants. |
| 624 | |
| 625 | |
| 626 | Caption: In Table 5, the base case scenario (nirsevimab is offered to all infants entering |
| 627 | the RSV season born within or outside the RSV season) is compared to the standard of |
| 628 | care (palivizumab is offered to a select segment of high-risk preterm infants). Clinical |
| 629 | and cost outcomes are presented. |

Figure 1. Modification formula for health-related inputs

$$HI_{i,j} = \alpha \left(\frac{X_i}{\bar{X}_i}\right) * \left(\frac{X_i}{Z_i}\right)$$

Let X = palivizumab - eligible infants; Y = preterm infants;

- Z = term infants (point of reference)

```
636
        HI_{i,i}: Canadian health input (e.g. inpatient hospitalization) for infant subgroup i and
```

- age at time of infection j
- α : Canadian modification value
- X_i : Infant subgroup X (e.g. palivizumab eligible infants) for age at time of infection i
- \bar{X} : Average % of health input for infant subgroup X (e.g. palivizumab – eligible infants)
- Z_i : Point of reference infant subgroup (i.e. term infants) for age at time of infection i

Figure 2. Modification formula for cost-related inputs [scenarios S1a, S1b based on Rafferty et al. (2023)]

 $Cost Input_{ii} = M * Y_{ii}$

645
$$Modifier M = \frac{\sum \Theta_{ij} \mu}{\sum_{ij} X_{ij} Y_{ij}}$$

j: health outcome (*i*. *e*. *inpatient* hospitalization, *ICU*, *mechanical ventilation*)


X: total number of in – season and out – season cases generated by the static model

Y:multiplier (reference) values based on the US costing distribution matrix

Θ: Case counts of healthcare utilization

 μ : Average, median, or midpoint values derived from the Canadian literature


663 Figure 3. Model structure



The population includes infants less than two years of age, and it is divided into three subgroups to account for the differential individual risks of lower respiratory tract disease (LRTDs) and for the groups assessed in the nirsevimab clinical trials: Palivizumab-eligible infants, Preterm infants, and Late Preterm or Term infants. Infants experience different health events and require use of medical resources such as primary care (PC) and emergency room (ER) visits as well as hospitalizations. During the inpatient health state, infants might be in standard pediatric ward, admitted in intensive care unit (ICU) and requiring mechanical ventilation (MV). Non-medically events as referred to in this figure (in grey) are modelled in a scenario analysis, as well as all-cause LRTD hospitalizations, and complications following an RSV related hospitalization.

Abbreviations: ER = emergency room; ICU = intensive care unit; LRTD = lower respiratory tract disease; MV =
 mechanical ventilation; PC = primary care; RSV = respiratory syncytial virus; wGA = week of gestational age.

687 Figure 4. Deterministic sensitivity analysis for price per dose (PPD)



688 689

690 Abbreviations PPD: price per dose; DSA: deterministic sensitivity analysis

691 Figure Captions

Figure 1 Caption: The formula in Figure 1 was constructed to utilize average Canadian values

and generate data points specific to health outcome, age of infection, and sub-group of interest,

assuming a similar distribution of cases to the United States.

Figure 2 Caption: The formula in Figure 2 was constructed to utilize existing aggregate Canadian

696 costs and generate specific outcome and sub-group specific costing data for RSV-related

697 hospitalization, ICU admission, and mechanical ventilation, assuming a similar distribution of

698 costs to the United States.

699 Figure 3 Caption: Figure 3 provides a visual illustration of the static model with the

corresponding subgroups, health outcomes, and timeframe of interest.

Figure 4 Caption: The DSA was executed for all scenarios. Since each scenario only applies

variations in the costing matrix, providing one DSA (base case) was considered appropriate to

understand how each parameter affects the price per dose. Figure 3 was provided to illustrate the

base case scenario for all infants within and outside the RSV season at the \$40,000 cost per

705 QALY threshold.